1 Multidisciplinary Thoracic Oncology Program and Thoracic Oncology Research Group Baptist Cancer Center, Memphis, TN 38120, USA ; 2 Department of Thoracic Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
Transl Lung Cancer Res. 2015 Aug;4(4):424-31. doi: 10.3978/j.issn.2218-6751.2015.08.01.
Surgical resection remains the most important curative treatment modality for non-small cell lung cancer, but variations in short- and long-term surgical outcomes jeopardize the benefit of surgery for certain patients, operated on by certain types of surgeons, at certain types of institutions. We discuss current understanding of surgical quality measures, and their role in promoting understanding of the causes of outcome disparities after lung cancer surgery. We also discuss the use of minimally invasive surgical resection approaches to expand the playing field for surgery in lung cancer care, and end with a discussion of the future role of surgery in a world of alternative treatment possibilities.
手术切除仍然是非小细胞肺癌最重要的治愈性治疗方式,但某些患者的短期和长期手术结果存在差异,这使得某些类型的外科医生在某些类型的医疗机构为这些患者进行手术的获益受到了威胁。我们讨论了当前对手术质量措施的理解,以及它们在促进对肺癌手术后结果差异原因的理解方面所起的作用。我们还讨论了微创外科切除方法的应用,以扩大肺癌治疗中手术的应用范围,最后讨论了在替代治疗可能性的世界中手术的未来作用。